Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GOVX
GOVX logo

GOVX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy GeoVax Labs Inc (GOVX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.380
1 Day change
1.47%
52 Week Range
34.750
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

GeoVax Labs Inc (GOVX) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock exhibits weak financial performance, bearish technical indicators, and lacks positive catalysts or significant trading signals. Analysts have downgraded the stock, citing elevated execution risks and limited near-term catalysts. Given the investor's preference for long-term growth, this stock does not align with their goals.

Technical Analysis

The technical indicators for GOVX are bearish. The MACD is slightly positive but contracting, RSI is neutral at 27.121, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot point of 1.589, with key support at 1.364 and resistance at 1.814. Overall, the technical setup does not suggest a strong entry point.

Positive Catalysts

  • NULL identified. There are no recent news updates or significant positive developments for the company.

Neutral/Negative Catalysts

  • Analyst downgrade citing limited near-term catalysts and elevated execution risks. Financial performance shows a 100% YoY revenue drop and a significant EPS decline (-65.68% YoY). The stock also lacks significant hedge fund or insider trading activity.

Financial Performance

GeoVax Labs reported poor financial performance in Q3 2025. Revenue dropped to $0 (-100% YoY), while net income improved slightly to -$6,318,914 (+8.66% YoY). EPS declined significantly to -7.79 (-65.68% YoY). Gross margin remained flat at 100%. Overall, the financials indicate a struggling company with no revenue and ongoing losses.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Jason Kolbert of D. Boral Capital downgraded the stock from Buy to Hold, citing a constrained near-term outlook, limited catalysts, and tightening capital resources. No price target was provided. Analysts are cautious about the stock's near-term prospects.

Wall Street analysts forecast GOVX stock price to rise
2 Analyst Rating
Wall Street analysts forecast GOVX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.360
sliders
Low
10
Averages
12
High
14
Current: 1.360
sliders
Low
10
Averages
12
High
14
D. Boral Capital
Jason Kolbert
Buy -> Hold
downgrade
AI Analysis
2026-02-19
Reason
D. Boral Capital
Jason Kolbert
Price Target
AI Analysis
2026-02-19
downgrade
Buy -> Hold
Reason
D. Boral Capital analyst Jason Kolbert downgraded GeoVax Labs to Hold from Buy without a price target. The firm says the company is facing a "more constrained" near-term outlook with limited catalysts and tightening capital resources. While the company continues to advance GEO-MVA as a potential diversification solution within the mpox vaccine landscape, its near-term execution risk is elevated, the analyst tells investors in a research note.
Roth Capital
Jonathan Aschoff
Buy
maintain
$14
2025-12-26
Reason
Roth Capital
Jonathan Aschoff
Price Target
$14
2025-12-26
maintain
Buy
Reason
Roth Capital analyst Jonathan Aschoff contends that December was "a strong month" GeoVax Labs, citing the EMA issuing formal Scientific Advice affirming that the company's proposed nonclinical package is acceptable, three peer-reviewed publications highlighting clinical and preclinical data for GEO-CM04S1 and Gedeptin, and two U.S. patents being either allowed or issued. The firm has a Buy rating and $14 price target on GeoVax shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GOVX
Unlock Now

People Also Watch